iPS Cells & Regenerative Medicine– category –
-
Made Scientific: 85,000 sq-ft cell therapy facility acquisition
Contract Pharma USA Overview Made Scientific has acquired an 85,000 square-foot cell therapy manufacturing facility in East Norriton, Pennsylvania, from National Resilience. The facility, designed for clinical development through commerc... -
FDA vs EMA: CGT manufacturing and potency assay requirements
Rhizome AI USA Overview Significant structural differences exist between FDA and EMA manufacturing controls and GMP requirements for Cell and Gene Therapy (CGT) at the IND/CTA stage. The FDA maintains more explicit early-stage requiremen... -
Ryoncil: Mesoblast’s new FDA potency assay specs for GVHD drug
Mugglehead Australia Overview Mesoblast has received FDA approval for a new potency assay, the T-cell Proliferation Inhibition BioAssay (TIBA), for Ryoncil (remestemcel-L), its treatment for pediatric steroid-refractory acute Graft-versu... -
iPSC Cell Therapy: 2026 roadmap for BeiGene, BlueRock and Fate
BioInformant USA Overview As of 2026, leading companies such as BeiGene, BlueRock Therapeutics, and Fate Therapeutics are actively advancing diverse pipelines of iPSC-derived cell therapeutics. Notably, Fate Therapeutics has secured FDA ... -
iPS Cells & Regenerative Medicine Weekly Report September 20, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report September 20, 2026 (PDF) — Download Weekly Report September 20, 2026 (PDF) — DownloadDownload 🎙 Podcast Septe... -
Ori Biotech Secures $120M, 10-Year Partnership for Automated Cell Therapy Manufacturing; Vyriad’s In Vivo CAR-T Clears IND
RegMedNet UK Overview Ori Biotech announced a 10-year, $120 million partnership with an undisclosed biopharma firm to automate cell therapy manufacturing using its IRO platform, aiming to improve patient access. Concurrently, Vyriad secu... -
Vertex Pharmaceuticals Initiates Phase I/II for Type 1 Diabetes Cell Therapy, Expands Renal Pipeline at Morgan Stanley Conference
MarketBeat USA Overview Vertex Pharmaceuticals unveiled its ambitious growth strategy beyond cystic fibrosis at the Morgan Stanley 24th Global Healthcare Conference, emphasizing its renal pipeline and a groundbreaking cell therapy progra... -
Tempest Therapeutics Licenses Senlang’s In Vivo CAR-T Platform, Targeting Relapsed/Refractory Multiple Myeloma with Dual BCMA/GPRC5D Approach in Phase I Trial
AllSci USA Overview Tempest Therapeutics has secured an exclusive license option for Hebei Senlang Biotechnology's CD7-targeting lentiviral in vivo CAR-T platform and related product candidates. This platform generates CAR-T and CAR-NK c... -
Indian Health Ministry Issues Advisory to States, UTs to Regulate Stem Cell Therapy; Limits Autism Application to Clinical Trials
ETV Bharat India Overview The Indian Ministry of Health and Family Welfare has issued a comprehensive advisory to all states and Union Territories, reinforcing regulations on stem cell therapies following directives from the Supreme Cour... -
UA Little Rock Secures Grant to Develop 3D Tissue Scaffold Replicating Human Intestinal Villi-Crypt Structures
University of Arkansas at Little Rock News USA Overview Dr. Sujan Ghosh at the University of Arkansas at Little Rock has received a grant to develop a novel 3D tissue scaffold capable of accurately mimicking the villi-crypt structures of...
